BDBM296429 US10112942, Example 163::US10112942, Example 166::US10112942, Example 183::US10137124, Example 163::US10555944, Example 163::US10953005, Example 163::US20230322769, Compound Selpercatinib::US20240174674, Compound Selpercatinib

SMILES COc1ccc(CN2C3CC2CN(C3)c2ccc(cn2)-c2cc(OCC(C)(C)O)cn3ncc(C#N)c23)cn1

InChI Key InChIKey=XIIOFHFUYBLOLW-UHFFFAOYSA-N

Data  33 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 37 hits for monomerid = 296429   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of human wild type RETMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of wildtype RET (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 0.420nMAssay Description:Inhibition of recombinant RET V804L (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 0.420nMAssay Description:Inhibition of human RET V804L mutantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 0.700nMAssay Description:Inhibition of recombinant RET M918T (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 0.800nMAssay Description:Inhibition of human RET V804M mutantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of GST-3C fused human RET (705 to 1013 residues) expressed in sf9 baculovirus expression system using 5-FAM- peptide as substrate preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 1.98nMAssay Description:The activity assay method for the above kinases was established by homogeneous time-resolved fluorescence (HTRF), and the inhibitory activity of the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
US Patent

TargetCoiled-coil domain-containing protein 6/Proto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jiangsu Chia Tai Fenghai Pharmaceutical

US Patent
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 2.07nMAssay Description:The activity assay method for the above kinases was established by homogeneous time-resolved fluorescence (HTRF), and the inhibitory activity of the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [M918T](Human)
Jiangsu Chia Tai Fenghai Pharmaceutical

US Patent
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 2.17nMAssay Description:The activity assay method for the above kinases was established by homogeneous time-resolved fluorescence (HTRF), and the inhibitory activity of the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 2.80nMAssay Description:Inhibition of wild type rearranged during transfection kinase (unknown origin) preincubated for 1 hr followed by addition of development agent incuba...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Jiangsu Chia Tai Fenghai Pharmaceutical

US Patent
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 5.09nMAssay Description:The activity assay method for the above kinases was established by homogeneous time-resolved fluorescence (HTRF), and the inhibitory activity of the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
US Patent

LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 5.66nMAssay Description:The three drug-resistant mutant RET enzymes were each pre-incubated with different concentrations of test compounds (in the inhibition rate test of t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 14nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 14nMpH: 7.4Assay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 14nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 14nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 15.1nMpH: 7.4Assay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
US Patent

LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 24.1nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Jiangsu Chia Tai Fenghai Pharmaceutical

US Patent
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 24.1nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Jiangsu Chia Tai Fenghai Pharmaceutical

US Patent
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 24.1nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
US Patent

LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 24.1nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Jinan University

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 29.3nMpH: 7.4Assay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Jiangsu Chia Tai Fenghai Pharmaceutical

US Patent
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 34.1nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
US Patent

LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 43.2nMAssay Description:1.3 Preparation of 1× Kinase Buffer4 volume of distilled water was added to 1 volume of enzyme buffer 5×; 5 mM MgCl2; 1 mM DTT.1.4 Screening Methoda)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 43.2nMAssay Description:a) 10 nL of compound dilution was transferred to each well of the test plate;b) the compound plate was centrifuged at 1000 g for 1 min;c) the test pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
US Patent

LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 74nMAssay Description:The three drug-resistant mutant RET enzymes were each pre-incubated with different concentrations of test compounds (in the inhibition rate test of t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Jiangsu Chia Tai Fenghai Pharmaceutical

US Patent
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 84.2nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
University of Arkansas For Medical Sciences

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 100nMAssay Description:Inhibition of recombinant VEGFR2 (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 151nMAssay Description:The three drug-resistant mutant RET enzymes were each pre-incubated with different concentrations of test compounds (in the inhibition rate test of t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
University of Arkansas For Medical Sciences

Curated by ChEMBL
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 172nMAssay Description:The activity assay method for the above kinases was established by homogeneous time-resolved fluorescence (HTRF), and the inhibitory activity of the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
US Patent

LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 473nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
US Patent

LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 531nMAssay Description:The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
US Patent

LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 531nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 531nMAssay Description:RET G810R: The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 531nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Jiangsu Chia Tai Fenghai Pharmaceutical

US Patent
LigandPNGBDBM296429(US10112942, Example 163 | US10112942, Example 183 ...)
Affinity DataIC50: 2.75E+3nMAssay Description:Inhibition of hERG Potassium Channel by Prepared Compounds The final concentrations of test compounds were all prepared on the day of experiment and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
US Patent